DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Evaluation of Efficacy and Safety of Highly Purified Urofollitropin in Chinese Females Undergoing an Assisted Reproductive Technology (ART) Program

Information source: Ferring Pharmaceuticals
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Infertility

Intervention: Highly Purified Urofollitropin (Drug); Recombinant Human Follitropin Alfa (Drug)

Phase: Phase 3

Status: Completed

Sponsored by: Ferring Pharmaceuticals

Official(s) and/or principal investigator(s):
Clinical Development Support, Study Director, Affiliation: Ferring Pharmaceuticals

Summary

Evaluate the efficacy and safety of of Highly Purified Urofollitropin for Injection Compared to Recombinant Human Follitropin Alfa for Injection in Chinese Females Undergoing an Assisted Reproductive Technology (ART) Program.

Clinical Details

Official title: A Randomized, Assessor-blinded, Parallel Group, Multi-center, Non-inferiority Study Investigating the Efficacy and Safety of Highly Purified Urofollitropin for Injection Compared to Recombinant Human Follitropin Alfa for Injection in Controlled Ovarian Stimulation in Chinese Females Undergoing an Assisted Reproductive Technology (ART) Program

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: The number of retrieved oocytes per cycle

Secondary outcome:

The follicles development

The fertilization rate

Implantation rate

Cycle cancellation rate

The positive serum β-hCG/hCG rate

The clinical pregnancy rate

The clinical pregnancy rate

The ongoing pregnancy rate

Total gonadotropin dose administered and the duration of gonadotropin treatment

Serum E2 (Estradiol) concentrations

Frequency and severity of adverse events

Frequency and severity of injection site reactions

Eligibility

Minimum age: 20 Years. Maximum age: 39 Years. Gender(s): Female.

Criteria:

Inclusion Criteria:

- Signed informed consent form, prior to screening evaluations

- In good physical and mental health

- Chinese Females between the ages of 20-39 years.

- Body mass index (BMI) is ≥ 18. 5 and < 28 kg/m2

- Female diagnosed for at least one year (i. e., before screening) with tubal

infertility, unexplained infertility, male factor infertility

- Regular menstrual cycles of 24-35 days (both inclusive), presumed to be ovulatory

- Documented evidence of at least one of the following within ninety (90) days prior to

down regulation treatment:

- mid-luteal phase serum progesterone level > 5ng/mL, or

- late luteal phase endometrial biopsy with < 3 days lag, or

- biphasic basal body temperature chart, or

- mid-cycle urinary LH (Luteinizing hormone)surge

- Early follicular phase (day 2-3), serum levels of FSH within limits

(1-12IU/L)(results obtained within 90 days prior to down regulation treatment)

- LH, PRL (prolactin), E2 (Estradiol), P (progesterone), total testosterone levels

within normal range for the clinical laboratory or considered not clinically significant by the investigator (results obtained within 90 days prior to down regulation treatment)

- TSH (thyrotropin) levels within normal limits for the clinical laboratory or

considered not clinically significant by the investigator, or secondary to exogenous thyroid medication (results obtained within 90 days prior to down regulation treatment)

- Negative serum Human Immunodeficiency Virus (HIV) antibody, and TPPA (Treponema

Pallidum antibodies)/ RPR (Rapid Plasma Reagin) tests (results obtained within 90 days prior to down regulation treatment)

- Early follicular phase total antral follicle (diameter 2-10 mm) count ≥ 6 and ≤ 25

for both ovaries combined (results obtained within 3 months prior to down regulation treatment)

- Transvaginal ultrasound documenting presence and adequate visualisation of both

ovaries, uterus and adnexa without evidence of significant abnormality (e. g.no endometrioma greater than 3 cm, no ovarian cysts > 35 mm or enlarged ovaries which would contraindicate the use of down regulation treatment, no hydrosalpinx) within ninety (90) days prior to down regulation treatment

- Hysterosalpingography, hysteroscopy, saline infusion sonography or transvaginal

ultrasound documenting a uterus consistent with expected normal function (e. g.no evidence of clinically interfering uterine fibroids defined as submucous or intramural fibroids larger than 3 cm in diameter, no polyps and no congenital structural abnormalities which are incompatible with pregnancy) within 1 year prior to down regulation treatment. This also includes women who have been diagnosed with any of the above medical conditions but have had them surgically corrected.

- A minimum of one cycle without treatment with fertility modifiers (e. g., oral

contraceptives) during the last menstrual cycle before down regulation treatment

- Willing to accept a maximum of two embryos transferred in the fresh cycle

- Willing to use an adequate barrier method of contraception or refrain from

intercourse from 2 weeks before start of down regulation and throughout the down regulation period Exclusion Criteria:

- Any pregnancy within last three (3) months prior to screening

- Known past or current thrombophlebitis or thromboembolism including venous thrombosis

disease and active or recent arterial thrombosis disease

- Three or more controlled ovarian stimulation cycles for IVF/ICSI (In vitro

fertilization/Intracytoplasmic sperm injection) prior to screening

- Previous IVF or ART failure related to a sperm/fertilization problem which resulted

in unsuccessful fertilization and no related medical conditions improved

- Known history of poor ovarian response in a previous controlled ovarian stimulation

cycle for IVF/ICSI

- Known history of excessive ovarian response in a previous controlled ovarian

stimulation cycle for IVF/ICSI

- Known severe OHSS (Ovarian hyperstimulating syndrome) in a previous controlled

ovarian stimulation cycle.

- Known history of polycystic ovary disease (PCOD) associated with anovulation

- Known endometriosis

- Known abnormal results of cervical examination of clinical significance obtained

within 1 year prior to screening

- Abnormal vaginal bleeding of undetermined origin

- Known tumors of the ovary, breast, uterus, adrenal gland, pituitary or hypothalamus

- Known current active pelvic inflammatory disease

- Known history of recurrent miscarriage

- Known malformations of the sexual organs incompatible with pregnancy

- According to the judgment of the investigator, abnormal laboratory value of renal or

hepatic function is clinically significant

- Known current (3 months prior to screening) or past (1 year prior to screening) abuse

of alcohol or drugs, and/or current or past smoking habit of more than 10 cigarettes per day

- Any known endocrine or metabolic abnormalities (pituitary, adrenal, pancreas, liver

or kidney) which can compromise participation in the trial with the exception of controlled thyroid function disease

- Known history of chemotherapy (except for gestational conditions) or radiotherapy

- According to the judgment of the investigator, abnormal laboratory value is

clinically relevant

- Use of any non-registered investigational drugs during 3 months before screening or

previous participation in the study

Locations and Contacts

Chinese PLA General Hospital, Beijing, Beijing, China

Peking Union Medical College Hospital, Beijing, Beijing, China

Peking University First Hospital, Beijing, Beijing, China

Peking University People's Hospital, Beijing, Beijing, China

Sun Yat-sen Memorial Hospital Sun Yat-sen University, Guangzhou, Guangdong, China

The third Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China

Tongji Hospital Tongji Medical College of HUST Tongji Medical College Huazhong University of Science & Technology, Wuhan, Hubei, China

The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China

ShengJing Hospital of China Medical University, Shenyang, Liaoning, China

Sichuan Provincial People's Hospital, Chengdu, Sichuan, China

Tianjin Medical University General Hospital, Tianjin, Tianjin, China

Additional Information

Starting date: October 2013
Last updated: June 15, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017